Clinical Trial Update: Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease [Phase 1, Phase 2]

View source ↗

Summary

This update summarizes a Phase 1/2 clinical trial evaluating HQK-1001 for safety, tolerability, and pharmacokinetics in patients with sickle cell disease. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HQK-1001

Snippet

Sponsor: HemaQuest Pharmaceuticals Inc. | Conditions: Sickle Cell Disease | Phase 1, Phase 2 | Status: COMPLETED